Slingshot members are tracking this event:

ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ZIOP Community voting in process

Additional Information

Additional Relevant Details
In two prior trials the first generation CD19-specific CAR+ T cells, patient-derived (autologous) or donor-derived (allogeneic) T cells were administered to recipients with advanced CD19-expressing leukemias and lymphomas after hematopoietic stem-cell transplantation (HSCT). Results demonstrated an apparent doubling of survivals compared to historical controls.The second-generation Sleeping Beauty CAR+ T cells employ a revised CAR construct designed to improve persistence and anti-tumor response over the first generation therapy. Additionally, this investigational treatment is independent of HSCT.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 09, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Study, Cd19, Car T-cell Therapy, Advanced Lmphoid Malignancies